Viromed Medical AG (ISIN: DE000A40ZVN7) has successfully completed the capital increase announced today, according to a release distributed via NEWMEDIAWIRE. The company placed a total of 450,000 new registered no-par value shares at a placement price of EUR 4.50 per share, generating gross proceeds of approximately EUR 2 million. The proceeds are earmarked to finance the company's working capital.
Subject to the registration of the implementation of the capital increase in the commercial register, Viromed's share capital will increase from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The capital increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of the shareholders' subscription rights. This means existing shareholders were not offered the opportunity to subscribe to the new shares on a pro-rata basis, a move that can allow for a faster execution and broader investor participation but dilutes existing holdings.
The completion of the capital increase is significant for Viromed as it bolsters the company's financial position and provides the resources needed to fund its ongoing operations. The fresh capital will be used for working capital purposes, which typically covers day-to-day operational expenses such as inventory, salaries, and supplier payments. For a company focused on the distribution of innovative cold plasma technology for medical applications, adequate working capital is essential to maintain inventory levels, support sales efforts, and manage the ramp-up of its business activities.
Viromed Medical AG, listed on the stock exchange since October 2022, specializes in the development, manufacture, and distribution of medical products. Its operating business centers on the distribution of cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. The company can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. Additional information about the company is available at www.viromed-medical-ag.de.
The capital increase, with the exclusion of subscription rights, may be viewed as a signal of confidence by the investors who subscribed to the new shares, as they are committing capital without the typical protection of a rights offering. For existing shareholders, the dilution effect is a consideration, but the injection of EUR 2 million in working capital could strengthen the company's ability to execute its growth strategy and invest in the commercialization of its cold plasma technology. The transaction also underscores the continued interest in medical technology ventures, particularly those with innovative platforms like cold plasma, which has applications in wound healing, disinfection, and other medical areas.
The original release can be viewed on www.newmediawire.com.
